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Abstract
Background: Disease risk assessments based on common genetic variation have gained widespread attention and
use in recent years. The clinical utility of genetic risk profiles depends on the number and effect size of identified
loci, and how stable the predicted risks are as additional loci are discovered. Changes in risk classification for
individuals over time would undermine the validity of common genetic variation for risk prediction. In this analysis,
we quantified reclassification of genetic risk based on past and anticipated future GWAS data.
Methods: We identified disease-associated SNPs via the NHGRI GWAS catalog and recent large scale genome-wide
association study (GWAS). We calculated the genomic risk for a simulated cohort of 100,000 individuals based on a
multiplicative odds ratio model using cumulative GWAS-identified SNPs at four time points: 2007, 2009, 2011, and
2013. Individuals were classified as Higher Risk (population adjusted odds >2), Average Risk (between 0.5 and 2),
and Lower Risk (<0.5) for each time point and we compared classifications between time points for breast cancer
(BrCa), prostate cancer (PrCa), diabetes mellitus type 2 (T2D), and cardiovascular heart disease (CHD). We estimated
future reclassification using the anticipated number of undiscovered SNPs.
Results: Risk reclassification occurred for all four phenotypes from 2007 to 2013. During the most recent interval
(2011-2013), the degree of risk reclassification ranged from 16.3 % for CHD to 24.4 % for PrCa. Many individuals
classified as Higher Risk at earlier time points were subsequently reclassified into a lower risk category. From 2011
to 2013, the degree of such downward risk reclassification ranged from 24.9 % for T2D to 55 % for CHD. The
percent of individuals classified as Higher Risk increased as more SNPs were discovered, ranging from an increase of
5 % for CHD to 9 % for PrCa from 2007 to 2013. Reclassification continued to occur when we modeled the
discovery of anticipated SNPs based on doubling current sample size.
Conclusion: Risk estimates from common genetic variation show large reclassification rates. Identifying disease-
associated SNPs facilitates the clinically relevant task of identifying higher-risk individuals. However, the large
amount of reclassification that we demonstrated in individuals initially classified as Higher Risk but later as Average
Risk or Lower Risk, suggests that caution is currently warranted in basing clinical decisions on common genetic
variation for many complex diseases.
Background
Risk assessments for common, multifactorial disease
based on common genetic variation have long been her-
alded as a potential clinical application of genomic data
[1–6]. The possibility of informative disease risk predic-
tion has gained widespread attention in recent years due
to the thousands of disease risk-associated single nucleo-
tide polymorphisms (SNPs) identified from genome-
wide association studies (GWAS). Moreover, disease risk
prediction based on genetic variation has become in-
creasingly familiar in broader society in part due to the
availability and marketing of direct-to-consumer (DTC)
genomic testing products [7, 8]. While there are con-
cerns about accurately estimating and communicating
common complex risk information [9, 10], customers of
DTC genetic testing services discuss their genetic testing
results with their physicians and have follow-up testing
related to their results [11, 12]. The FDA’s 2013 order to
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the DTC genomic testing company 23andMe is based in
part on the concern that customers may inappropriately
use their results to influence their use of medical ser-
vices [13, 14].
A future role for using personal genetic variation in
disease risk assessment continues to be of intense inter-
est and efforts to optimize prediction models for many
common medical problems continue. As the technical
and cost barriers to whole genome sequencing have de-
creased significantly in recent years, the application of
whole genome sequencing in patients with undiagnosed
disorders is growing [15], the sequencing of healthy pop-
ulations has begun to be explored, and disease risk as-
sessment for common diseases has been demonstrated
as a possible application of whole genome sequencing
data [16, 17]. In the MedSeq Project, a randomized clin-
ical trial exploring the integration of whole genome se-
quencing information in clinical care, we are exploring
the strengths and limitations of current approaches to
risk assessment from common genetic variation, with
specific attention to clinical utility and interpretability,
and developed a common genetic variant risk assess-
ment for cardiovascular phenotypes [18, 19].
The predictive ability and resulting clinical utility of
risk evaluation from common genetic variation depends
on the number and effect size of the loci associated with
the probability of developing a given phenotype, and has
to date been found to generally be modest for most
multifactorial conditions. Non-genetic factors such as
diet and other exposures will also continue to be import-
ant predictors for multifactorial phenotypes such as
diabetes. Nevertheless, identifying a subgroup of the
population that is at high genetic risk offers clinically
relevant opportunities such as enhanced screening or
targeted lifestyle modification initiatives.
Many questions remain concerning risk modeling,
such as the ability of risk-associated SNPs to capture the
genetic architecture for a phenotype and interactions be-
tween variants and epigenetic effects [20]. It is reason-
able to assume, however, that as additional GWAS are
undertaken and overall sample sizes increase, new risk-
associated SNPs will be discovered and effect estimates
of currently used SNPs will be modified. In addition to
enabling novel disease pathway and therapeutic target
identification, these SNPs will explain larger proportions
of heritability for multifactorial conditions. The genetic
component of predictive models will therefore improve
and, depending on an individual’s genotype, risk predic-
tions for a given individual will often change. The likeli-
hood of large shifts in risk classification for any given
individual as more disease-associated SNPs are identified
is not known, however. Moreover, whether the potential
for clinically meaningful change in risk assessment di-
minishes or increases has not been fully explored.
The stability of predicted genetic risks as additional
loci are discovered is therefore an important, largely un-
explored factor. If genetic risk assessments for a given
individual vary significantly over time as new loci are in-
cluded in the predictive model for a specific condition, it
could undermine the validity and utility of common gen-
etic variation for risk prediction that is based upon early
SNP discoveries. For example, if an EKG or even a car-
diac stress test were ordered for an individual due to an
increased genetic risk assessment of coronary heart dis-
ease, but subsequent additions of SNPs or effect modifi-
cations for existing SNPs in the model caused a
reclassification of the individual to a lower risk category,
the individual would have undergone unwarranted test-
ing, with the associated unnecessary risk and cost. Con-
versely, if an individual were originally classified as
Lower Risk for a condition and does not pursue standard
screening tests or lifestyle modification due to the re-
sults, but subsequent identification of high-risk SNPs re-
sults in a reclassification to the Higher Risk group, then
false reassurance from the initial results might result in
missed opportunities for disease risk modification.
A reclassification rate is the percentage of individuals
who change predefined risk categories based on change
in prediction model or over time. Past published efforts
to explore the question of reclassification based on gen-
etic risk predictions include a 2009 study that compared
risk reclassification for diabetes mellitus type 2 (T2D)
based on one SNP, an 18-SNP model, and the 18-SNP
model in addition to non-genetic risk factors and found
significant reclassification rates between the three
models [21]. We are not aware, however, of updated or
more comprehensive evaluations of genetic risk reclassifi-
cation. The rapid and continuing expansion of the number
of statistically significant SNPs in the literature and GWAS
catalog offers an opportunity to assess risk reclassification
both on recent data and using projected future data based
on larger sample sizes. While reclassification rates should
eventually diminish as more risk-associated SNPs are dis-
covered, it is not clear if reclassification rates will stabilize,
increase or decline in as the next waves of GWAS data are
published.
With our primary interest and focus on the near-
future clinical applicability of risk prediction from com-
mon genetic variation, we analyze reclassification based
on past, present, and future GWAS results using the
NHGRI GWAS Catalog for four phenotypes [22]. We
explore the impact of discovering new SNPs along with
modification of effects sizes for four phenotypes: (1)
breast cancer (BrCa); (2) prostate cancer (PrCa); (3) dia-
betes mellitus type 2 (T2D); and (4) coronary heart dis-
ease (CHD). We estimate reclassification and model
predictive ability for these four phenotypes based on a
simulated cohort of 100,000 individuals, first looking
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backwards at the risk prediction model for each pheno-
type from GWAS data since 2007. We then explore the
impact on reclassification based on a hypothetical future
GWAS with double the sample size of the most recent
two-stage GWAS for each phenotype.
Methods
To emulate the methods most widely used by DTC gen-
omic companies and others, our risk prediction model
for each phenotype uses SNPs that have been reported
at genome-wide significance [10, 16, 23]. Though no
best practice has been established for calculating disease
risk from multiple risk alleles, we use the multiplicative
odds ratio (OR) model in combining the SNPs for each
phenotype (equivalent to additive log odds as described
in Purcell et al.) [10, 19, 24]. To assess how risk predic-
tion could change over time, we account for the con-
tinuing discovery of new SNPs and the change in effect
size in time for previously identified SNPs.
SNP identification and filtering
A SNP was considered associated with the disease of
interest if the P value was less than the genome wide sig-
nificant cutoff of 5 × 10-8. SNPs were identified from the
National Human Genome Research Institute (NHGRI)
catalog [22] and supplemented by data from four recent
large scale studies [25–28]. If one of the recent large-
scale studies reported a position for a previously discov-
ered SNP that was different from what was specified in
the NHGRI catalog, it was set to the value in the
NHGRI catalog. We examined four different diseases:
breast cancer (BrCa), prostate cancer (PrCa), T2D, and
coronary heart disease (CHD) at four different time
points: the end of 2007, 2009, 2011, and 2013. The 2009
risk calculations would therefore include the SNPs that
had been reported 2009 or prior.
We considered SNPs within 500 kb of each other to be
at the same locus. We included SNPs at a locus in a step-
wise fashion, starting with the SNP with the most signifi-
cant P value at a given time point and then adding
subsequent SNPs in order of significance if the r2 between
the candidate SNP and all SNPs already included was
below 0.75. Thresholds of 0, 0.25, 0.5, and 1 were also
considered to assess the sensitivity of the genetic risk dis-
tribution to pruning on different thresholds of LD. We re-
trieved LD info from the SNP Annotation and Proxy
(SNAP) database [29]. Using r2 thresholds between 0.25
and 0.75 produced similar results. Using an r2 threshold of
1 (that is, include all SNPs at the locus) produced larger
genetic risk gradients and area-under-the-curve (AUC)
values, but likely overestimates the effect of each locus by
double-counting the effect of causal variants tagged by
multiple highly correlated SNPs. We adopted this proced-
ure to mimic procedures that rely on catalogs of published
GWAS results [17]; more accurate modeling of the contri-
bution of multiple SNPs at a locus can be achieved though
conditional or haplotype modeling.
Simulating cohort
To assess the reclassification in genetic risk values, we
estimated the distribution of genetic ORs in cases and in
controls. We simulated a cohort of 100,000 individuals
of European descent for each of the four conditions eval-
uated. Assuming the incidence of disease is rare, the dis-
tribution of genetic ORs in this cohort approximates the
distribution of genetic relative risks in controls. (We re-
peated the calculations in Tables 3 and 5 explicitly using
the distribution in controls for a range of disease inci-
dences from near 0 to 10 %. Results did not appreciably
vary from those presented here; differences were mostly
under 1 %.) We simulated the genotype for all of the
genome-wide significant SNPs discovered from 2007 to
2013, based on the number of SNPs present at each locus.
The genotype of each locus was generated independently
of other loci. If a locus consisted of one SNP, the genotype
was simulated from a binomial distribution using allele
frequencies from the 1000 Genomes or HapMap Euro-
pean cohorts, depending upon availability [30, 31]. When
a locus contained more than one SNP, a two-fold ap-
proach was used. If phased data were available (HapMap
or 1000 genomes), the genotype was then bootstrapped
from the phased haplotypes for the 100,000 individuals.
When phase data were not available, haplotype frequen-
cies were estimated via the EM algorithm [32] and then
diplotypes were simulated via a multinomial distribution.
Regardless of availability of phase, we removed related in-
dividuals using the BioQ notation [33].
To analyze genetic risk values across over time, the
genotypic ORs were simulated for SNPs that had been
discovered by the four selected dates (2007, 2009, 2011,
2013) and the resulting SNPs were then pruned based
on linkage disequilibrium (LD) (see above). The genetic








Here km is the number of SNPs known to be associ-
ated with a disease at the time point m, and gi,j is the
genotype for individual i at SNP j. If at a later time point
a study reported a more significant P value for a SNP
than had previously been reported, the OR was set to
that reported value. The effect size of the SNP is thus
allowed to change over time. Thus the ORj,m indicates
the OR at time point m for SNP j. The odds were then
normalized by the population mean from each simulated
cohort.




The normalized OR represents the odds of disease for
simulated individual i with genotype gi = (gi1,…,.gij) rela-
tive to the population average odds. While the exact for-
mula used by DTC companies is unique to each
company, the mathematical approach used by 23andMe
and others is based on some version of the multiplicative
odds model used in our study [10].
The cumulative distribution function for genetic ORs
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where Pr(g) is estimated using the distribution of geno-
types in the simulated cohort. This calculation assumes
the disease is rare so that the genetic OR approximates
the genetic relative risk.
Reclassification and AUC
Normalized odds were calculated for the simulated indi-
viduals using the known genome-wide significant SNPs
known, and their associated ORs for common complex
diseases, at four different time points: 2007, 2009, 2011,
and 2013. Individuals could be classified at three levels
of risk: Lower Risk (Oi <0.5); Moderate Risk (0.5 ≤Oi ≤
2); and Higher Risk (Oi > 2) [34, 35]. The percent reclas-
sification was calculated as the percentage of individuals
on the off-diagonal of a 3 × 3 table classification table
looking between time points. The net reclassification
index was calculated as the proportion of cases whose
reclassified risk category increased minus the proportion
of cases whose reclassified risk category decreased, plus
the proportion of controls whose reclassified risk category
decreased minus the proportion of controls whose reclas-
sified risk category increased. We chose these cutoffs not
because they correspond to any specific clinical decision
algorithm, but because they have been used previously as
a general benchmark for whether genetic information pro-
vides potentially actionable information [35].
The AUC was also calculated at each time point as [36]:




; a ¼ μD−μD
σD
; b ¼ σ D
σD
Where φ is the cumulative distribution for a normal
distribution and D represents the case population and D
represents the control population. The parameters are
all in terms of the distribution of the log risks: μD = the
mean log genetic OR in controls, σ D = the standard de-
viation of the log genetic OR in controls, and μD and σD
are the corresponding values for cases.
Estimating distribution of genetic ORs based on future
GWAS
We also estimated the total number of common SNPs
that are potentially detectable by GWAS, given a large
enough sample size. The number of causal SNPs was
calculated via the ‘bin’ method described by Park et al.
[37], which groups SNPs based on effect size e = β22q(1-
q). Here β and q are the log OR and minor allele fre-
quencies for a SNP, Mj is the number of SNPs observed
in bin i; pj is the power to observe a SNP with effect size
corresponding to bin j, given the largest sample size
studied up to the time point [38]:





MT,j is thus the total estimated number of SNPs in that
bin [37] and k is the number of disease-associated SNPs
reported in the recent large-scale GWAS studies [25–28,
39]. To simplify power calculations, for this analysis we
only used the SNPs reported in recent combined two-
stage design studies [25–28, 39]. We are assuming in
these calculations that the SNPs in these GWAS studies
are the only SNPs that have been reported. Thus the
total number of SNPs may be less than the amount re-
ported above.
Reclassification after doubling the sample size
In order to assess how much current estimates of risk
will vary as a result of additional GWAS discoveries in
the near future, we also explored how much reclassifica-
tion would be observed for each phenotype using SNPs
hypothetically discovered from a GWAS with double the
sample size of the most recent GWAS studies. For each
SNP from the recent GWAS, we calculated the power
(pj) to observe said effect size in a single-stage study
with double the sample size. We then predicted that the
total number of SNPs we would observe with that effect
size would equal:
pjMT ;j
Using the new set of predicted SNPs for each pheno-
type, we simulated the genotypes for the newly predicted
set of SNPs for a sample of 100,000 individuals of
European descent, assuming each new SNP was in a
unique locus. For example, if for a specific SNP reported
in the most recent two-stage GWAS, we expect there to
be 10 total SNPs with the same effect size and we have a
predicted power of 0.8 to detect the SNP in a double
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sample size study, we simulated eight SNPs of that effect
size and minor allele frequency. In fact, we simulate
slightly more by simulating the ceiling of pjMT,j. Reclas-
sification was then assessed using the SNPs in the 2013
GWAS vs. when we had the sum of pjMT,j for all SNPs.
We then calculated the AUC in these simulated datasets.
Since the AUC from the ‘current’ here is based just on
the SNPs from a subset of all GWAS studies, it will not
be directly comparable to the AUC calculated using the
NHGRI catalog and the recent large scale GWAS.
Results
The number of SNPs meeting the selected P value and
LD criteria outlined above increased steadily for all the
phenotypes over successive time windows, with the most
dramatic increase across all phenotypes occurring from
2011 to 2013 (Fig. 1). As the number of SNPs identified
increased, the average effect size per SNP generally de-
creased (Fig. 2). As more SNPs were discovered, the pro-
portion of individuals classified as Higher Risk also
increased (Table 1) and the risk distribution for each
phenotype widened (Fig. 3). The proportion of individ-
uals that were reclassified increased substantially as
more SNPs were discovered (Table 2). The highest 2-
year reclassification rate for each phenotype occurred
from 2011 to 2013, and the average reclassification rate
from 2011 to 2013 across the phenotypes was 20.4 %
and ranged from 16.3 % to 24.4 %. This was also the
time period that saw the greatest increase in identified
SNPs. Most of this reclassification reflected an improve-
ment in the risk model, as indicated in the positive net
reclassification indices in Table 3. Using the three risk
categories (Lower, Average, and Higher), the majority of
reclassification from 2011 to 2013 was due to movement
between the Lower Risk and the Average Risk categories
(see Additional file 1: Tables S1a, S2a, S3a, S4a). If
the risk categories are grouped into Higher Risk ver-
sus Lower or Average Risk, the reclassification pro-
portions from 2011 to 2013 are 7.0 %, 5.2 %, 5.5 %,
and 7.4 % for BrCa, CHD, T2D, and PrCa, respect-
ively. The full reclassification tables can be seen in
Additional file 1: Tables S1–S4.
We separately analyzed reclassification among those
who were in the Higher Risk group in 2011 (Table 4).
This was done to assess how much movement there was
for individuals most likely to have changes in clinical
management due to being classified at high risk. For
BrCa, 42 % of the individuals who had been classified as
high risk in 2011 moved to a lower risk classification in
2013. Reclassification proportions from 2011 to 2013 for
the other three phenotypes ranged from 25 % to 55 %.
The vast majority of this reclassification was from
Higher Risk to Average Risk, with little movement from
Higher Risk to Lower Risk (Additional file 1: Table S5).
The AUC for the risk prediction models increased
modestly from 2007 to 2013, with a mean increase over
Fig. 1 Total number of SNPs over a 2-year time period. The total number of SNPs reaching genome-wide significance with each disease increased
over time. The dashed lines indicate the number of SNPs remaining after pruning out SNPs based on LD structure
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each 2-year period since 2007 of 0.034 across the four
phenotypes. Two examples of larger increases include
PrCa from 2007 to 2009 (0.591 - >0.667) and BrCa from
2011 to 2013 (0.634 - >0.671) (Table 5). This may be due
to the large amount of SNPs that were discovered in the
Michailidou et al. paper released in early 2013 [25]. For
PrCa, there were 20 SNPs discovered from 2007 to 2009,
bringing the number from five to 25 [27, 40]. The AUC
values reported in Table 5 are generally slightly higher
than those reported in the literature when validating risk
models using similar number of SNPs [20, 41–55]. This
is likely due to the compounded effect of overestimates
in published individual-SNP ORs [56, 57].
When projecting the performance of risk prediction
models based on hypothetical future GWAS with twice
the sample size of the current largest studies, we ob-
served marked reclassification, on the order of that ob-
served comparing the model based on 2013 SNPs to
that based on the 2007 SNPs: reclassification rates were
0.40, 0.12, 0.31, and 0.27 for BrCa, CHD, T2D and PrCa,
respectively (Table 6). The net reclassification rates were
again positive, indicating model improvement: net re-
classification rates were 0.34, 0.082, 0.21, and 0.21 for
BrCa, CHD, T2D, and PrCa, respectively (Table 6 and
Additional file 1: Table S6). The proportion of indi-
viduals moving from Higher Risk to the Lower or
Moderate Risk category remained large, ranging from
0.40 to 0.51 (Table 6). Individuals currently classified
as Lower Risk or Average Risk were slightly less likely
to be reclassified after doubling the sample size. For
example, 30 % of individuals currently classified as Lower
Risk for CHD were reclassified to Average Risk (none
were reclassified as Higher Risk), while only 11 % of those
currently classified as Average Risk were reclassified as
Lower Risk or Higher Risk.
One limitation to using reclassification rates as a
primary endpoint is that the degree of change in risk
for individuals and the cohort as a whole is obscured.
For example, one potential explanation for the reclas-
sification rates we observed is that many individuals
had small absolute changes in odds which nonetheless
resulted in a change in risk categorization based on
our defined odds thresholds. Across all phenotypes,
roughly half of individuals (51 %) had a change in the
adjusted odds of 0.2 or less from 2011 to 2013. How-
ever, 17 % of individuals had changes in adjusted
odds of greater than 0.5.
Fig. 2 Mean SNP effect size by a 2-year time period. With larger sample sizes, GWAS were able to detect SNPs with smaller and smaller effect
sizes. This brought down the mean effect size for each disease by year (with the exception of PrCa in 2009 which saw a slight bump)
Table 1 Proportion of individuals at high risk (>2× average), by
year
Disease 2007 2009 2011 2013
BrCa 0.002 0.029 0.051 0.079
CHD 0 0.003 0.026 0.049
T2D 0.020 0.055 0.094 0.103
PrCa 0.029 0.076 0.099 0.112
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Discussion
Individuals’ genetic risk prediction for common complex
diseases will change as our knowledge of the genetic un-
derpinnings of these traits changes. At some point, as
the known genetic contribution increases and ap-
proaches the total (known and unknown proportion)
genetic contribution of common SNPs, the change in
individuals’ predictions with every new discovery will di-
minish. We have shown that, depending on phenotype, be-
tween 18 % and 50 % of individual risk estimates were
reclassified over the time period of 2007 to 2013. Rather
than diminishing, the impact of new GWAS-discovered
risk alleles remains high and may in fact be increasing, as
studies reach a sample size ‘tipping point’ and have power
Fig. 3 Risk distributions for each phenotype at 2007, 2009, 2011, and 2013. As more SNPs were discovered the distribution of cell type risks
widened. This led to more individuals being placed in the tail ends of the distribution as time progressed
Table 2 Reclassification proportion based on year of SNP set
BrCa CHD T2D PrCa
2007 vs. 2009 0.083 0.003 0.126 0.269
2009 vs. 2011 0.131 0.091 0.38 0.224
2011 vs. 2013 0.237 0.163 0.172 0.244
2007 vs. 2013 0.295 0.177 0.426 0.504
Entries represent proportion of subjects whose genetic risk category (lower: <0.5×
average; moderate: between 0.5× and 2.0× average; higher: >2× average) changes
from one year to the next
Table 3 Net Reclassification Index based on year of SNP set
BrCa CHD T2D PrCa
2007 vs. 2009 0.067 0.004 0.095 0.211
2009 vs. 2011 0.075 0.065 0.254 0.131
2011 vs. 2013 0.137 0.089 0.061 0.121
2007 vs. 2013 0.274 0.146 0.389 0.510
The Net Reclassification Index is defined in the section ‘Reclassification
and AUC’
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to reliably detect many alleles with smaller effects. Eventu-
ally we will reach a point of diminishing returns, where lar-
ger and larger studies will fail to detect any novel SNPs, but
for the time being we are still in the discovery stage.
The projected reclassification rate in the near future
partly reflects the modest predictive power of current
genetic risk prediction algorithms. It also reflects the fact
that many common complex phenotypes appear to fol-
low a polygenic inheritance model, with many SNPs of
small effect contributing to disease risk. Previous GWAS
have had low power to detect most of these SNPs, so
published SNPs to date likely reflect only a portion of
the heritability attributable to common genetic variation.
Increasing numbers of individuals classified as Higher
Risk and Lower Risk
We observed that the proportions of individuals in the
Higher Risk category, defined as greater than 2× the
mean risk, increased over time. Specifically, we noted a
gradual increase in the proportion of individuals at
greater than twice the average genetic risk from less than
3 % in 2007 to a total of 5 % to 11 % in 2013 across the
four phenotypes. Additionally, increased proportions in
the Higher Risk category were noted when risk estimates
were projected using double the GWAS sample size.
This result was anticipated given that as more risk-
associated SNPs are discovered, the total risk distribu-
tion widens, and therefore the proportion of individuals
at increased risk increases slightly. In other words, dis-
covering new SNPs increases the probability of discover-
ing individuals at the extremes of genetic risk burden.
Genetic risk assessment for a given multifactorial condi-
tion is most relevant for those who fall in the Higher Risk
or Lower Risk categories. In theory, as certainty around risk
estimates improve, early or enhanced screening protocols
and stricter control of risk factors through lifestyle modifi-
cation or medical intervention may be warranted for indi-
viduals with increased genetic risk profiles. On the other
hand, individuals with relatively low genetic risk factors
may benefit or avoid disadvantage if they are subject to less
screening or fewer preventative measures. For the vast ma-
jority with average genetic risk, little change would appear
warranted from conventional screening and prevention
measures. Currently and in the near future, however, the
emphasis is and will be likely placed on patients with
increased risk. As individuals in the extremes of the
predicted risk distribution are the most important to
identify from a clinical decision-making perspective,
the possibility of identifying more such individuals
over time offers a reason to suggest that risk classifica-
tion based on common variation may have increased
clinical utility in the future.
Potential clinical implications of high reclassification rates
There are pressing questions concerning the validity of
risk estimates for those interested in translating the
current discoveries from the GWAS era into clinical rec-
ommendations, and this study is not intended to address
these issues. Our analysis does not address or attempt to
account for non-genetic components of risk estimation
for any phenotype, such as dietary factors, smoking, or
other exposures. Non-genetic risk factors are important
components of risk, and for some phenotypes, contrib-
ute more to risk of developing disease than does genetic
variation. In clinical assessment, therefore, evaluation of
non-genetic risk factors will remain important even as
risk-prediction models based on common genetic vari-
ation improve. Our study, however, focuses only on the
genetic risk and how the rapidly evolving data about
common genetic variation impacts risk categorization
Table 4 Proportion of higher risk (>2× average) individuals
reclassified from Higher Risk to Average Risk or Lower Risk
categories (<2× average)
BrCa CHD T2D PrCa
2007 vs. 2009 0.614 ————— 0.04 0.378
2009 vs. 2011 0.325 0.622 0.661 0.248
2011 vs. 2013 0.418 0.550 0.249 0.309
2007 vs. 2013 0.586 ————— 0.667 0.532
Dashes indicate that no individuals were classified as higher risk at one of the
relevant time points
Table 5 AUC based on year of SNP set
BrCa CHD T2D PrCa
Year 2007 0.574 0.58 0.606 0.596
Year 2009 0.612 0.582 0.642 0.671
Year 2011 0.636 0.611 0.695 0.717
Year 2013 0.672 0.636 0.712 0.748
Table 6 Reclassification when sample size doubled
Future SNPs Future SNPs
BrCa CHD
Current SNPS Risk Low Average High Low Average High
Low 0.074 0.026 0.000 0.016 0.007 0
Average 0.265 0.508 0.083 0.076 0.857 0.033
High 0.001 0.021 0.021 0.000 0.004 0.006
T2D PrCa
Current SNPS Risk Low Average High Low Average High
Low 0.120 0.037 0 0.040 0.016 0.000
Average 0.182 0.535 0.065 0.178 0.676 0.066
High 0.000 0.027 0.034 0.000 0.012 0.012
Entries are the proportion of individuals who are classified as Lower Risk
(<0.5× average), Average Risk (between <0.5× average and >2× average), or
Higher Risk (>2× average) risk based on: (1) currently known risk SNPs (rows)
and (2) the risk SNPs known after a hypothetical future GWAS that doubles
the size of the largest current GWAS (columns)
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over time. Moreover, we have not addressed the import-
ant issue of risk model calibration—whether those pre-
dicted to be at high risk are indeed at high risk. Model
calibration requires large genotyped cohorts with exten-
sive follow-up, and is beyond the scope of our analyses.
A key component of the validity of risk projections
based on common genetic variation, however, is whether
risk predictions are stable as additional SNPs are identi-
fied. In other words, what proportion of individuals from
the clinically important subgroup currently classified as
Higher Risk remains in the Higher Risk category as more
SNPs are discovered for a given phenotype? If reclassifi-
cation is low for those in the Higher Risk category, then
considering modifications to screening or preventative
measures may be warranted based on current risk esti-
mates. However, if a large proportion of individuals
identified as Higher Risk based on early models were
later classified as Average Risk or Lower Risk, additional
caution would be warranted before basing clinical deci-
sions on a predicted increased risk for a phenotype.
Our analysis, based only on the identification of new
risk alleles, shows a significant proportion of reclassifica-
tion for individuals determined to be in the Higher Risk
category for each phenotype for the 2-year period as re-
cent as 2011 to 2013. For an individual who underwent a
risk evaluation based on known risk-associated SNPs for
CHD in 2011, there was a 55 % probability that they
would subsequently be reclassified into a lower risk group
in 2013 and therefore may have received misguided inter-
vention. Though the downward reclassification rates are
lower for other phenotypes, even the smallest rate is 25 %
for T2D. Projections based on doubling the GWAS sam-
ple size suggest that even much larger samples than are
currently available do not resolve the ongoing instability,
with projected reclassification rates for individuals at high
risk near 50 % for all four phenotypes.
We stress that the changes in reclassification rates and
net reclassification indices over time that we report here
are for illustration purposes only. Both reclassification
rates and net reclassification indices are sensitive to the
choice of risk thresholds used [58]. The ultimate criteria
for benchmarking prediction models against each other
depend on the specifics of the clinical setting (including
the existence of agreed-upon risk thresholds, specific in-
terventions, and costs and benefits of these interventions)
[59, 60]. Precisely because such important evaluations are
so context dependent, we have not undertaken them here.
Conclusions
In sum, our analysis shows significant instability in pre-
dicted risk from common genetic variation for four multi-
factorial phenotypes. While the results may not be
unexpected given the known limitations of the risk
prediction using genetic data, they underscore the
caution that should be used in interpreting results for
an individual patient. Moreover, this analysis demonstrates
a consequence of the limited predictive ability of current
genetic models, specifically increased reclassification rates
in the face of new data. At the same time, reclassification
rates should eventually begin to decrease as additional
SNPs are identified and increasing proportions of the gen-
eral population will fall into the clinically relevant Lower
Risk and Higher Risk categories, resulting in the opportun-
ity for potentially impactful interventions particularly for in-
dividuals in the Higher Risk group. Moreover, the major
improvements in number of known SNPs in our analysis
underscore the progress that has been and will be made.
Hope for potential clinical utility is warranted even in the
face of the significant unresolved limitations and
challenges.
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